EQS-News

Heidelberg Pharma AG: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022 - Seite 2

Currently, the trial is enrolling patients in cohort 4; further data is expected in Q1 2023.

Prof. Andreas Pahl, Chief Scientic Officer of Heidelberg Pharma, commented: “We congratulate Magenta on their great progress with the development candidate MGTA‑117 and the preliminary but promising data from this clinical trial. We are very pleased that an ADC based on our proprietary ATAC technology has shown positive efficacy data in humans without unexpected or serious treatment-related adverse events. The presented data confirms our view that cancer therapies with ATACs can provide highly effective and well-tolerated treatment.”

MGTA-117 is an Amanitin-based ADC consisting of a CD117 antibody and Amanitin as payload. It was developed under a partnership with Heidelberg Pharma that grants Magenta exclusive worldwide development and marketing rights for antibody-drug conjugates using an Amanitin payload and targeting CD117.

About Heidelberg Pharma's proprietary ATAC technology
Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. ATACs are ADCs whose active ingredient is the mushroom toxin Amanitin. Amanitin inhibits mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma
Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its innovative ATAC technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. The proprietary technology platform is being applied to develop the Company’s own therapeutic ATACs as well as in third-party collaborations. The lead candidate HDP-101 is a BCMA ATAC in clinical development for multiple myeloma. Further ATAC candidates are being developed against different targets such as CD37, PSMA or GCC each in the indications non-Hodgkin's lymphoma, metastatic castration-resistant prostate cancer or gastrointestinal tumors such as colorectal cancer.